Nigel Irwin

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

Paula L. McClean, Nigel Irwin, Roslyn Cassidy et al. · American Journal of Physiology-Endocrinology and Metabolism · 2007 · 232 citations

Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action by Daily (Pro3)GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Related Diabetes

Victor A. Gault, Nigel Irwin, Brian D. Green et al. · Diabetes · 2005 · 167 citations

Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets

Victor A. Gault, Paula L. McClean, Roslyn Cassidy et al. · Diabetologia · 2007 · 128 citations · Full text

Insulin Resistance, Metabolic Syndrome, Obesity +11

A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice

Victor A. Gault, Vikas K. Bhat, Nigel Irwin et al. · Journal of Biological Chemistry · 2013 · 120 citations · Full text

Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality

A. Mieczkowska, Nigel Irwin, Peter R. Flatt et al. · Bone · 2013 · 114 citations · Full text

Obesity, Metabolic Syndrome, Insulin Signaling +11